Reviva Net Income Per E B T from 2010 to 2024
| RVPHW Stock | USD 0.23 0.04 21.05% |
Net Income Per E B T | First Reported 2010-12-31 | Previous Quarter 1 M | Current Value 1.1 M | Quarterly Volatility 360.9 K |
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 10 K, Net Interest Income of 523.9 K or Interest Income of 523.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.5. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
Reviva | Net Income Per E B T |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Reviva Stock Analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.